Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Lathara

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Plos One|April 24, 2020
Advancing clinical cohort selection with genomics analysis on a distributed platformJaclyn M Smith, Melvin Lathara, Hollis Wright, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 9, 2024
Toward Deploying a Deep Learning Model for Diagnosis of RhabdomyosarcomaDavid Joon Ho, Narasimhan P Agaram, Arthur O Frankel, et al.
Cold Spring Harbor Molecular Case Studies|April 3, 2020
Defining an embryonal rhabdomyosarcoma endotypeCora A Ricker, Kenneth Crawford, Kevin Matlock, et al.
Cold Spring Harbor Molecular Case Studies|January 13, 2021
Refractory alveolar rhabdomyosarcoma in an 11-year-old maleCora A Ricker, Andrew D Woods, William Simonson, et al.
European Journal of Pharmacology|February 5, 2020
In vitro benchmarking of NF-κB inhibitorsAlexandria P Harrold, Megan M Cleary, Narendra Bharathy, et al.
Scientific Reports|June 13, 2026
System for study of diverse cellular composition in alveolar rhabdomyosarcomaGuak-Kim Tan, Kavya Kannan, Hollis Wright, et al.
Biochemical and Biophysical Research Communications|July 12, 2022
Sensitization of osteosarcoma to irradiation by targeting nuclear FGFR1Jin-Ah Kim, Noah E Berlow, Melvin Lathara, et al.
Oncotarget|October 4, 2017
Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcomaNarendra Bharathy, Matthew N Svalina, Teagan P Settelmeyer, et al.
Cold Spring Harbor Molecular Case Studies|August 7, 2021
Metastatic pediatric sclerosing epithelioid fibrosarcomaAndrew D Woods, Reshma Purohit, Laura Crocker Mitchell, et al.
Pediatric Blood & Cancer|October 25, 2021
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumorAndrew D Woods, Noah E Berlow, Michael V Ortiz, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Plos One|April 24, 2020
Advancing clinical cohort selection with genomics analysis on a distributed platformJaclyn M Smith, Melvin Lathara, Hollis Wright, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 9, 2024
Toward Deploying a Deep Learning Model for Diagnosis of RhabdomyosarcomaDavid Joon Ho, Narasimhan P Agaram, Arthur O Frankel, et al.
Cold Spring Harbor Molecular Case Studies|April 3, 2020
Defining an embryonal rhabdomyosarcoma endotypeCora A Ricker, Kenneth Crawford, Kevin Matlock, et al.
Cold Spring Harbor Molecular Case Studies|January 13, 2021
Refractory alveolar rhabdomyosarcoma in an 11-year-old maleCora A Ricker, Andrew D Woods, William Simonson, et al.
European Journal of Pharmacology|February 5, 2020
In vitro benchmarking of NF-κB inhibitorsAlexandria P Harrold, Megan M Cleary, Narendra Bharathy, et al.
Scientific Reports|June 13, 2026
System for study of diverse cellular composition in alveolar rhabdomyosarcomaGuak-Kim Tan, Kavya Kannan, Hollis Wright, et al.
Biochemical and Biophysical Research Communications|July 12, 2022
Sensitization of osteosarcoma to irradiation by targeting nuclear FGFR1Jin-Ah Kim, Noah E Berlow, Melvin Lathara, et al.
Oncotarget|October 4, 2017
Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcomaNarendra Bharathy, Matthew N Svalina, Teagan P Settelmeyer, et al.
Cold Spring Harbor Molecular Case Studies|August 7, 2021
Metastatic pediatric sclerosing epithelioid fibrosarcomaAndrew D Woods, Reshma Purohit, Laura Crocker Mitchell, et al.
Pediatric Blood & Cancer|October 25, 2021
Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumorAndrew D Woods, Noah E Berlow, Michael V Ortiz, et al.
Pageof 2